Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01976143 · ClinicalTrials.gov registry record · Phase 1
A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety
A Phase 1 study, sponsored by Nektar Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT01976143 is a Phase 1 study that has completed, run by Nektar Therapeutics. The registered enrollment target is 33 participants.
The verdict
NCT01976143, a Phase 1 study, has completed, sponsored by Nektar Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate the effect of NKTR-102 on the QT/QTc interval in patients with advanced or metastatic solid tumors
Interventions
- DRUG NKTR-102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2014-02 |
| Est. Completion | 2016-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01976143
The ClinicalTrials.gov registry entry for NCT01976143 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nektar Therapeutics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NKTR-102 is the first listed.
NCT01976143 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01976143 about?
NCT01976143 is a clinical study titled "A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety". The purpose of this research study is to evaluate the effect of NKTR-102 on the QT/QTc interval in patients with advanced or metastatic solid tumors
What is the current status of trial NCT01976143?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2014-02. Estimated completion is 2016-09.
What interventions are being tested in trial NCT01976143?
The interventions under investigation include: NKTR-102 (DRUG).
Who is sponsoring clinical trial NCT01976143?
This trial is sponsored by Nektar Therapeutics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.